Glutathione is the body's most abundant internal antioxidant, and its levels fall with age. The strongest finding is that body stores can be raised — by mouth or by supplying the raw materials the body uses to make it. Beyond that, longevity benefits remain plausible but unproven. The injected skin-whitening form is risky and best avoided. (Full Review)

Protocol

Standard Oral

250–1,000 mg/day

Reduced (Setria) glutathione; 1,000 mg/day gives larger increases over months

Precursor (GlyNAC)

Glycine + N-acetylcysteine

Drives the cell's own synthesis; favored by researchers who doubt oral bioavailability

Dosing Schedule

Split, e.g. 250 mg twice daily

Morning or with meals; dividing doses may aid tolerability

Time to effect

Body Stores

1–6 months

Measurable within 1 month, continuing through 6 months in the oral trial

Skin Lightening

4–12 weeks

Effects regress after discontinuation

Functional Gains (Precursor)

16 weeks

Precursor-combination functional effects assessed at 16 weeks

Benefits

High: Replenishment of body glutathione stores; antidote role in acetaminophen toxicity

Medium: Reduction of oxidative stress markers; skin lightening and melasma improvement; improvement of aging-related function via precursor combination

Low: Enhanced immune cell activity; cardiometabolic marker improvement in diabetes

Speculative: Slowing of biological aging; neuroprotection and cognitive preservation

Contraindications

Intravenous skin-whitening use

Active chemotherapy (without oncology approval)

Pregnancy or breastfeeding (insufficient safety data)

Key Interactions

Nitrates / nitroglycerin (isosorbide dinitrate)

Chemotherapy agents (cisplatin, doxorubicin)

Acetaminophen (paracetamol)

Glutathione-raising supplements (N-acetylcysteine, glycine, alpha-lipoic acid, selenium, sulforaphane); charcoal and binders

Asthma (bronchospasm risk with N-acetylcysteine)

Risk & Side Effects

High: Serious adverse events with intravenous use

Medium: Gastrointestinal effects

Low: Theoretical reductive stress and blunting of adaptation; possible skin lightening as an unwanted effect

Speculative: Long-term safety of chronic high-dose use; allergic or hypersensitivity reactions

Monitoring

Marker	Target	Why
Whole-blood / red-cell glutathione (GSH)	Upper end of the assay's reference range	Most direct measure of body stores and supplementation response
GSH:GSSG ratio	Higher (more reduced) is better	Indicates the cell's oxidative balance
High-sensitivity C-reactive protein (hs-CRP)	< 1.0 mg/L	Tracks systemic inflammation often linked to oxidative stress
Gamma-glutamyl transferase (GGT)	< 20 U/L (men), < 15 U/L (women)	Liver enzyme tied to glutathione metabolism and oxidative stress
Fasting glucose / HbA1c	Glucose 70–85 mg/dL; HbA1c < 5.4%	Cardiometabolic markers shown to improve in glutathione-raising trials
Comprehensive metabolic panel (kidney/liver)	Within normal limits	Safety surveillance for liver and kidney function during chronic use

Cadence: Baseline, then around 8–12 weeks after starting, then every 6–12 months

Qualitative Assessment

Energy levels and reduced fatigue
Exercise recovery and perceived muscle soreness
Cognitive clarity and concentration
Skin tone or pigmentation changes (if using for cosmetic purposes)
General sense of well-being and resilience to illness

Glutathione for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment